Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin at 98.9%
Gross margin was 98.9% in Q1 FY2026. On a trailing-twelve-month basis it was 95.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
No Gross Margin data reported for this period type.
Gross Margin vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's LTM Mar 2026 gross margin of 95.0% is the highest of the 3 companies compared; the peer median is 79.1%.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | 95.0% | — | — |
| LTM Jun 2026 | 93.2% | +1.8 pp | +3.0 pp | |
| LTM Sep 2026 | 64.9% | -27.0 pp | -6.3 pp | |
| FY2025 | — | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | FY2025 | — | — | — |
| FY2025 | — | — | — | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — |
CTNMContineum Therapeutics, Inc. Class A Common Stock | FY2025 | — | — | — |
| FY2025 | — | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding RAPP) | 79.1% | -12.6 pp | -1.7 pp | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 15K | 112K | 839K | 1.02M |
| Gross Profit | (15K) | (112K) | (839K) | (1.02M) |
| Gross Margin | — | — | — | — |
| Research & Development | 9.12M | 28M | 60.94M | 94.79M |
| Selling, General & Admin | 1.37M | 8.07M | 22.12M | 30.31M |
| Operating Expenses | 10.35M | 36.07M | 82.22M | 125.1M |
| Depreciation & Amortization | 15K | 112K | 839K | 1.02M |
| EBITDA | (10.35M) | (34.66M) | (77.47M) | (124.08M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (10.37M) | (36.18M) | (83.06M) | (125.1M) |
| Operating Margin | — | — | — | — |
| Interest Income | 0 | 2.53M | 12.14M | 13.62M |
| Interest Expense | 285K | 0 | 0 | 0 |
| Other Income / Expenses | (285K) | 1.4M | 4.75M | 13.62M |
| Income Before Tax | (10.65M) | (34.78M) | (78.31M) | (111.48M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 10K | 0 | 0 |
| Net Income | (10.65M) | (34.79M) | (78.31M) | (111.48M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.29) | (0.95) | (3.78) | (2.86) |
| EPS (Diluted) | (0.29) | (0.95) | (3.78) | (2.86) |
| Weighted Avg Shares | 20.12M | 18.08M | 20.74M | 46.98M |
| Weighted Avg Shares (Diluted) | 20.12M | 18.08M | 20.74M | 46.98M |
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.